2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
47
Leukemia
28
Prostatic Neoplasms
21
Burkitt Lymphoma
17
Leukemia, Biphenotypic, Acute
15
Lymphoma
13
Leukemia, Myeloid, Acute
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Lymphoma, Large B-Cell, Diffuse
6
Recurrence
5
Lymphoma, Non-Hodgkin
5
Myelodysplastic Syndromes
4
Hodgkin Disease
4
Pituitary Neoplasms
3
Pancreatic Neoplasms
3
Neoplasms
3
Lymphoma, T-Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Large-Cell, Anaplastic
3
Lymphoma, B-Cell
3
Dendritic Cell Sarcoma, Interdigitating
3
Breast Neoplasms
3
Anemia, Refractory, with Excess of Blasts
3
Rhabdoid Tumor
2
Polycystic Ovary Syndrome
2
Obesity
2
Multiple Myeloma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Leukemia, Myelomonocytic, Juvenile
2
Interventions
Gels
2
Fulvestrant
2
Doxycycline
2
Dapsone
2
ruxolitinib
1
dexpanthenol
1
ceterizine hydrochloride
1
capivasertib
1
benralizumab
1
Triamcinolone Acetonide
1
Tetracycline
1
Sirolimus
1
Provitamins
1
Prednisone
1
Panitumumab
1
Minocycline
1
Loperamide
1
Irinotecan
1
Interviews as Topic
1
IFL protocol
1
Hydrocortisone
1
HIV Testing
1
Fibroblast Growth Factor 7
1
Erlotinib Hydrochloride
1
Clindamycin
1
Cetuximab
1
Anti-Bacterial Agents
1
Alpelisib
1
Acitretin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Exanthema
×
Hydrocortisone
×
Clear all
NCT00473083
2017-04-04
LUTRAERL
British Columbia Cancer Agency
Phase 2
Completed
150 enrolled
13 charts